All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How have oral hypomethylating agents changed the management of MDS?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the MDS Hub spoke with Guillermo Garcia-Manero, MD Anderson Cancer Center, Houston, US. We asked, How have oral hypomethylating agents changed the management of MDS?

How have oral hypomethylating agents changed the management of MDS?

Garcia-Manero discusses hypomethylating agents in the management of MDS and acute myeloid leukemia (AML). He goes on to describe the challenges associated with hypomethylating agents, such as the route of administration often being intravenous/subcutaneous. Lastly, he talks about oral hypomethylating agents such as azacitidine and decitabine.

 

Share: